Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea (Q36875372)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 May 2010

Language	Label	Description	Also known as
English	Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea	scientific article published on 17 May 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Larry Norton

11

0 references

3

object named as

Beverly Moy

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

12

object named as

Eric Winer

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

2

object named as

Nancy Lin

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Alyson Abbruzzi

7

object named as

Alyson Abbruzzi

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

Steven Sugarman

5

object named as

Steven Sugarman

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

Richard Steingart

9

object named as

Richard Steingart

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

author name string

Chau Dang

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Steven Come

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Patrick Morris

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Carol Chen

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sujata Patil

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Clifford Hudis

13

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

17 May 2010

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

28

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

2982-2988

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

The role of EGFR inhibition in the treatment of non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Recommended guidelines for the treatment of cancer treatment-induced diarrhea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

29 September 2017

Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 September 2018

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 September 2018

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 September 2018

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 September 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 September 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 December 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664034

4 December 2018

Effect of paclitaxel (Taxol) alone and in combination with radiation on the gastrointestinal mucosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.26.5900

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36875372&oldid=2117188148"